Skip to main navigation
MBX Bio Logo
  • Our Science
    • How PEPs™ Work
    • Development Programs
  • Platform
    • Our Pipeline
      • Canvuparatide
      • MBX 4219
      • MBX 5765
      • MBX 6XXX
  • Patients
    • Current Clinical Trials
    • Patient Stories
    • Resources & Advocacy
  • About Us
    • Mission
    • Core Values
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact IR
  • Careers
  • Contact Us

Presentations

Corporate Presentations

June 12, 2026
MBX ENDO 2026 Presentation 2.9 MB
May 11, 2026
MBX-May 2026 Obesity Day Presentation – Final 1.5 MB
May 7, 2026
MBX Company Overview - May 2026 1.6 MB
September 23, 2025
Once-Weekly Canvuparatide Avail™ Phase 2 Trial Topline Results 1.1 MB

Scientific Publications/Presentations

Efficacy and Safety of Once-Weekly Canvuparatide in Patients With Hypoparathyroidism: Results From Avail, a Phase 2, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Once-Weekly Canvuparatide in Patients With Hypoparathyroidism: Interim Analysis of the Open-Label Extension to the Phase 2, Double-Blind, Placebo-Controlled Avail Study
MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial
MBX Bio Logo

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics.

FOLLOW US

LinkedIn Logo

©2026 MBX Bio. All Rights Reserved.

  • Contact Us
  • Privacy Policy
  • Terms of Use

Website design by Mentus

©2026 MBX Bio. All Rights Reserved.

Website design by Mentus